Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Auxilium Pharmaceuticals
With that in mind, let's take a closer look at Auxilium's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Malvern, Pa. (1999)|
|Market Cap||$1.3 billion|
|Trailing-12-Month Revenue||$279.6 million|
|Management||CEO Adrian Adams (since 2007)
CFO James Fickenscher (since 2005)
|Return on Equity (average, past 3 years)||(48.9%)|
|Cash/Debt||$163.1 million / $0|
Par Pharmaceutical Cos.
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 31% of the 180 members who have rated Auxilium believe the stock will underperform the S&P 500 going forward.
This came up in a screen for stocks with the highest gains in the last 4 weeks. With a fair [book value per share] of $1.83 this company is greatly overvalued -- although that is expected in speculative pharma. It is almost breaking even, but only has $89 million in shareholders' equity as of 1Q12. Should be an easy red-thumb target.
If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.